Stemline Therapeutics (STML) Downgraded by BidaskClub

Stemline Therapeutics (NASDAQ:STML) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.

Other analysts have also issued reports about the company. HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 14th. Cowen reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Finally, ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Stemline Therapeutics presently has a consensus rating of “Buy” and an average price target of $33.75.

Shares of Stemline Therapeutics (STML) traded up $0.15 during midday trading on Friday, hitting $13.55. The stock had a trading volume of 108,486 shares, compared to its average volume of 176,674. Stemline Therapeutics has a twelve month low of $5.50 and a twelve month high of $16.20.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.11). Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. research analysts predict that Stemline Therapeutics will post -2.71 EPS for the current year.

In related news, insider David Gionco sold 4,250 shares of the business’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $13.43, for a total value of $57,077.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Kenneth Hoberman sold 11,983 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $14.18, for a total value of $169,918.94. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,216 shares of company stock worth $591,925. Corporate insiders own 16.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Voya Investment Management LLC bought a new stake in Stemline Therapeutics in the second quarter valued at about $102,000. Nationwide Fund Advisors increased its holdings in Stemline Therapeutics by 7.2% in the second quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 855 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Stemline Therapeutics by 40.1% in the second quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 5,522 shares during the last quarter. Alliancebernstein L.P. bought a new stake in Stemline Therapeutics in the second quarter valued at about $178,000. Finally, Rhumbline Advisers increased its holdings in Stemline Therapeutics by 18.5% in the second quarter. Rhumbline Advisers now owns 27,358 shares of the biopharmaceutical company’s stock valued at $252,000 after buying an additional 4,280 shares during the last quarter. 50.24% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/21/stemline-therapeutics-stml-downgraded-by-bidaskclub-2.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply